ALEXANDRIA, Va., July 15 -- United States Patent no. 12,661,411, issued on June 23, was assigned to Inimmune Corp. (Missoula, Mont.).
"Monoclonal antibody and vaccine targeting filamentous bacteriophage" was invented by Paul L. Bollyky (Stanford, Calif.), William Parks (Seattle) and Patrick Secor (Seattle).
According to the abstract* released by the U.S. Patent & Trademark Office: "Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-bindi...